Risk factors

Biovie (BIVI) risk factors

Item 1A of every Biovie Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open BIVI in Gloom →
Biovie's chart, financials and news, free in your browser.Open BIVI in Gloom →
  • FY2026 10-K risk factors
    44 risks1 dropped5 reworded

    No new risks were added, while the reverse-stock-split risk was removed after the July 7, 2025 split.

    Filed Aug 13, 2026
  • FY2025 10-K risk factors
    45 risks2 new2 dropped2 reworded

    BioVie updated share figures following a 1-for-10 reverse stock split on July 7, 2025. Dilution disclosures now explicitly mention potential anti-dilution adjustments for Acuitas warrants. Cash concentration dates were updated to July 31, 2025.

    Filed Aug 15, 2025
  • FY2024 10-K risk factors
    45 risks

    Biovie is a development-stage biopharmaceutical company with no approved products, commercial revenues, or manufacturing experience.

    Filed Sep 30, 2024